Preferred Label : finasteride;
MeSH definition : An orally active 3-OXO-5-ALPHA-STEROID 4-DEHYDROGENASE inhibitor. It is used as a
surgical alternative for treatment of benign PROSTATIC HYPERPLASIA.;
CISMeF synonym : frosst iberica brand of finasteride; MSD chibropharm brand of finasteride; merck frosst brand 2 of finasteride; merck sharp & dhome brand 2 of finasteride; cahill may roberts brand of finasteride; merck brand 2 of finasteride; MSD brand of finasteride; merck frosst brand 1 of finasteride; lipha brand of finasteride; merck brand 1 of finasteride; merck sharp & dohme brand 1 of finasteride;
MeSH hyponym : proscar; eucoprost; MK-906; propecia; Chibro-Proscar; Chibro Proscar; Propeshia; MK 906; MK906;
MeSH CAS label : 4-Azaandrost-1-ene-17-carboxamide, N-(1,1-dimethylethyl)-3-oxo-, (5alpha,17beta)-;
MeSH Related Number : 98319-26-7 (Finasteride);
Registry Number MeSH : 98319-26-7;
Wikipedia link : https://en.wikipedia.org/wiki/Finasteride;
Is substance : O;
UNII : 57GNO57U7G;
InChIKey : DBEPLOCGEIEOCV-WSBQPABSSA-N;
Origin ID : D018120;
UMLS CUI : C0060389;
ATC code(s)
Allowable qualifiers
CISMeF manual mappings
Currated CISMeF NLP mapping
Pharmacological action(s)
Record concept(s)
Related MeSH Supplementary Concept(s)
Semantic type(s)
UMLS correspondences (same concept)
Validated automatic mappings to BTNT
An orally active 3-OXO-5-ALPHA-STEROID 4-DEHYDROGENASE inhibitor. It is used as a
surgical alternative for treatment of benign PROSTATIC HYPERPLASIA.
https://ansm.sante.fr/actualites/reevaluation-europeenne-de-la-balance-benefice-risque-des-medicaments-contenant-du-finasteride-ou-du-dutasteride
2024
false
false
false
France
French
drug information
finasteride
Dutasteride
product surveillance, postmarketing
pharmacovigilance
---
https://ansm.sante.fr/actualites/finasteride-1-mg-propecia-et-generiques-ajout-de-mentions-dalerte-sur-les-boites-pour-renforcer-linformation-sur-les-effets-indesirables
2022
false
false
false
France
French
drug information
finasteride
finasteride
patient education handout
alopecia
administration, oral
mental disorders
Reduced libido (finding)
erectile dysfunction
Testicular Pain
Ejaculation Disorder
---
https://ansm.sante.fr/dossiers-thematiques/finasteride-1-mg-et-chute-de-cheveux
2022
false
false
false
France
French
continuity of patient care
alopecia
patients guideline
guideline
drug information
finasteride
finasteride
administration, oral
finasteride
androgenetic alopecia
---
https://www.ansm.sante.fr/actualites/lansm-renforce-linformation-sur-le-finasteride-1-mg-utilise-contre-la-chute-de-cheveux
2019
false
false
false
France
French
androgenetic alopecia
finasteride
finasteride
finasteride
patients guideline
drug information
alopecia
---
http://www.lecrat.eu/?s=Finast%C3%A9ride+-+exposition+paternelle
2019
false
false
false
France
French
scientific and technical information
paternal exposure
finasteride
---
http://www.has-sante.fr/portail/jcms/c_2752853/fr/chibro-proscar
2017
false
false
false
France
French
evaluation of the transparency committee
finasteride
treatment outcome
insurance, health, reimbursement
---
http://www.has-sante.fr/portail/jcms/c_2583323/fr/finasteride-arrow-lab
2015
false
France
French
drugs, generic
evaluation of the transparency committee
finasteride
administration, oral
prostatic hyperplasia
finasteride
5-alpha reductase inhibitors
insurance, health, reimbursement
urinary retention
prostatic hyperplasia
treatment outcome
---
Finasteride and suicidality
https://www.hc-sc.gc.ca/dhp-mps/medeff/bulletin/hpiw-ivps_2015-12-fra.php#a4.1
2015
false
false
false
Canada
French
English
finasteride
finasteride
5-alpha reductase inhibitors
suicidal ideation
self-injurious behavior
benign prostatic hyperplasia
finasteride
androgenetic alopecia
pharmacovigilance note
journal article
prostatic hyperplasia
alopecia
---
http://agence-prd.ansm.sante.fr/php/ecodex/extrait.php?specid=62828991
2012
France
summary of product characteristics
package leaflet
tablets
finasteride
---
http://agence-prd.ansm.sante.fr/php/ecodex/extrait.php?specid=69153913
2012
France
summary of product characteristics
package leaflet
finasteride
tablets
---
http://agence-prd.ansm.sante.fr/php/ecodex/extrait.php?specid=62517392
2012
France
summary of product characteristics
package leaflet
tablets
finasteride
---
http://agence-prd.ansm.sante.fr/php/ecodex/extrait.php?specid=60189609
2012
France
summary of product characteristics
package leaflet
tablets
finasteride
---
http://agence-prd.ansm.sante.fr/php/ecodex/extrait.php?specid=67145743
2012
France
summary of product characteristics
package leaflet
finasteride
tablets
---
http://agence-prd.ansm.sante.fr/php/ecodex/extrait.php?specid=68401423
2012
France
summary of product characteristics
package leaflet
finasteride
tablets
---
http://agence-prd.ansm.sante.fr/php/ecodex/extrait.php?specid=60658750
2012
France
summary of product characteristics
package leaflet
tablets
finasteride
---
http://agence-prd.ansm.sante.fr/php/ecodex/extrait.php?specid=66713965
2012
France
summary of product characteristics
package leaflet
tablets
finasteride
---
http://agence-prd.ansm.sante.fr/php/ecodex/extrait.php?specid=62489815
2012
France
summary of product characteristics
package leaflet
finasteride
tablets
---
http://agence-prd.ansm.sante.fr/php/ecodex/extrait.php?specid=66666939
2012
France
summary of product characteristics
package leaflet
tablets
finasteride
---
http://agence-prd.ansm.sante.fr/php/ecodex/extrait.php?specid=62316507
2012
France
summary of product characteristics
package leaflet
finasteride
tablets
---
http://agence-prd.ansm.sante.fr/php/ecodex/extrait.php?specid=69699613
2012
France
summary of product characteristics
package leaflet
finasteride
tablets
---
http://agence-prd.ansm.sante.fr/php/ecodex/extrait.php?specid=63127452
2012
France
summary of product characteristics
package leaflet
finasteride
tablets
---
http://agence-prd.ansm.sante.fr/php/ecodex/extrait.php?specid=63560165
2012
France
summary of product characteristics
package leaflet
finasteride
tablets
---
http://agence-prd.ansm.sante.fr/php/ecodex/extrait.php?specid=67836928
2012
France
summary of product characteristics
package leaflet
tablets
finasteride
---
http://agence-prd.ansm.sante.fr/php/ecodex/extrait.php?specid=60221042
2012
France
summary of product characteristics
package leaflet
finasteride
tablets
---
http://agence-prd.ansm.sante.fr/php/ecodex/extrait.php?specid=66921845
2012
France
summary of product characteristics
package leaflet
finasteride
tablets
---
http://agence-prd.ansm.sante.fr/php/ecodex/extrait.php?specid=69693507
2012
France
summary of product characteristics
package leaflet
finasteride
tablets
---
http://agence-prd.ansm.sante.fr/php/ecodex/extrait.php?specid=61897600
2012
France
summary of product characteristics
package leaflet
tablets
finasteride
---
http://agence-prd.ansm.sante.fr/php/ecodex/extrait.php?specid=69428925
2012
France
summary of product characteristics
package leaflet
finasteride
tablets
---
http://agence-prd.ansm.sante.fr/php/ecodex/extrait.php?specid=60123363
2012
France
summary of product characteristics
package leaflet
tablets
finasteride
---
http://agence-prd.ansm.sante.fr/php/ecodex/extrait.php?specid=62690191
2012
France
summary of product characteristics
package leaflet
tablets
finasteride
---
http://www.has-sante.fr/portail/jcms/c_1353463/avodart-dutasteride-chibro-proscar-finasteride-combodart-dutasteride-tamsulosine
http://www.has-sante.fr/portail/jcms/c_1353462/avodart-chibro-proscar-combodart-synthese-ct9291-9896-11612-12202
2012
false
France
French
Dutasteride
Dutasteride
administration, oral
insurance, health, reimbursement
dutasteride
tamsulosin and dutasteride
drug combinations
finasteride
finasteride
prostatic hyperplasia
finasteride
5-alpha reductase inhibitors
5-alpha reductase inhibitors
guidelines for drug use
sulfonamides
Tamsulosin
---
http://agence-prd.ansm.sante.fr/php/ecodex/extrait.php?specid=61672151
2012
France
summary of product characteristics
package leaflet
finasteride
tablets
---
http://agence-prd.ansm.sante.fr/php/ecodex/extrait.php?specid=67685458
2012
France
summary of product characteristics
package leaflet
tablets
finasteride
---
http://www.cochrane.org/fr/CD006015
2012
United Kingdom
France
French
meta-analysis
finasteride
prostatic hyperplasia
treatment outcome
5-alpha reductase inhibitors
prostatism
french abstract
---
https://www.healthycanadians.gc.ca/recall-alert-rappel-avis/hc-sc/2012/13665a-fra.php
2012
false
Canada
French
English
Dutasteride
sulfonamides
risk
administration, oral
prostatic neoplasms
finasteride
5-alpha reductase inhibitors
finasteride
finasteride
dutasteride
tamsulosin and dutasteride
drug combinations
prostatic hyperplasia
alopecia
androgenetic alopecia
pharmacovigilance note
Tamsulosin
---
http://www.has-sante.fr/portail/jcms/c_399217/chibro-proscar-5-mg-comprime-pellicule-boite-de-28-comprimes
http://www.has-sante.fr/portail/jcms/c_1058681/chibro-proscar
http://www.has-sante.fr/portail/jcms/c_1313141/chibro-proscar
http://www.has-sante.fr/portail/jcms/c_539638/chibro-proscar
http://www.has-sante.fr/portail/jcms/c_555406/chibro-proscar
http://www.has-sante.fr/portail/upload/docs/application/pdf/2012-10/chibro-proscar_05092012_ct_11612.pdf
2012
France
French
evaluation of the transparency committee
finasteride
administration, oral
prostatic hyperplasia
finasteride
5-alpha reductase inhibitors
finasteride
5-alpha reductase inhibitors
risk assessment
product surveillance, postmarketing
breast neoplasms, male
insurance, health, reimbursement
urinary retention
prostatic hyperplasia
prostatic hyperplasia
risk management
prostatic neoplasms
treatment outcome
---
https://www.healthycanadians.gc.ca/recall-alert-rappel-avis/hc-sc/2011/13530a-fra.php
2011
Canada
French
English
pharmacovigilance note
finasteride
risk
finasteride
finasteride
breast neoplasms, male
5-alpha reductase inhibitors
prostatic hyperplasia
alopecia
administration, oral
---
http://agence-prd.ansm.sante.fr/php/ecodex/extrait.php?specid=64993924
2009
France
French
finasteride
summary of product characteristics
package leaflet
---
http://www.cbip.be/Folia/Index.cfm?FoliaWelk=F36F04G
2009
Belgium
French
Dutch
finasteride
enzyme inhibitors
3-Oxo-5-alpha-Steroid 4-Dehydrogenase
alopecia
finasteride
5-alpha reductase inhibitors
drug information
---
http://revmed.ch/RMS/2005/RMS-2/30050
2005
true
Switzerland
French
prostatic hyperplasia
doxazosin
antihypertensive agents
finasteride
drug therapy, combination
journal article
---
https://minerva-ebp.be/fr/article/849
2004
false
false
minerva-ebm.be
Belgium
French
prostatic hyperplasia
doxazosin
finasteride
enzyme inhibitors
drug therapy, combination
treatment outcome
disease progression
enzyme inhibitors
doxazosin
finasteride
3-Oxo-5-alpha-Steroid 4-Dehydrogenase
adrenergic alpha-1 receptor antagonists
adrenergic alpha-1 receptor antagonists
5-alpha reductase inhibitors
5-alpha reductase inhibitors
critical appraisal or critical reading
---